MEI Pharma Inc. (MEIP)
| Bid | 1.91 |
| Market Cap | 13.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.22M |
| EPS (ttm) | -5.73 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -0.55 |
| Analyst | Hold |
| Ask | 2.27 |
| Volume | 2,256 |
| Avg. Volume (20D) | 9,101 |
| Open | 2.04 |
| Previous Close | 2.05 |
| Day's Range | 2.04 - 2.04 |
| 52-Week Range | 1.46 - 4.10 |
| Beta | 0.61 |
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cycl...
Analyst Forecast
According to 2 analyst ratings, the average rating for MEIP stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 243.98% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash PositionSAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continu...